PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för varespladib methyl. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

16 hits

Bibliografisk träff 2021-07-15

The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases.

Batsika CS, Gerogiannopoulou AD, Mantzourani C, Vasilakaki S, Kokotos G.

Expert Opin Drug Discov · review; journal article · DOI 10.1080/17460441.2021.1942835

Bibliografisk träff 2020-09-02

Varespladib (LY315920) inhibits neuromuscular blockade induced by Oxyuranus scutellatus venom in a nerve-muscle preparation.

Fontana Oliveira IC, Gutiérrez JM, Lewin MR, Oshima-Franco Y.

Toxicon · journal article · DOI 10.1016/j.toxicon.2020.08.023

Bibliografisk träff 2020-06-17

Varespladib Inhibits the Phospholipase A2 and Coagulopathic Activities of Venom Components from Hemotoxic Snakes.

Xie C, Albulescu LO, Still KBM, Slagboom J, Zhao Y, Jiang Z, Somsen GW, Vonk FJ, Casewell NR, Kool J.

Biomedicines · research-article; journal article · DOI 10.3390/biomedicines8060165

Bibliografisk träff 2020-02-20

Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms.

Gutiérrez JM, Lewin MR, Williams DJ, Lomonte B.

Toxins (Basel) · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/toxins12020131

Bibliografisk träff 2020-01-01

Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?

Santoso A, Heriansyah T, Rohman MS.

Curr Cardiol Rev · review-article; review; journal article · DOI 10.2174/1573403x15666190531111932

Bibliografisk träff 2019-06-20

The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites.

Williams HF, Layfield HJ, Vallance T, Patel K, Bicknell AB, Trim SA, Vaiyapuri S.

Toxins (Basel) · review-article; review; journal article · DOI 10.3390/toxins11060363

Bibliografisk träff 2018-11-17

Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of Micrurus fulvius (Eastern Coral Snake) Venom.

Lewin MR, Gilliam LL, Gilliam J, Samuel SP, Bulfone TC, Bickler PE, Gutiérrez JM.

Toxins (Basel) · research-article; journal article · DOI 10.3390/toxins10110479

Bibliografisk träff 2018-09-20

Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom.

Lewin MR, Gutiérrez JM, Samuel SP, Herrera M, Bryan-Quirós W, Lomonte B, Bickler PE, Bulfone TC, Williams DJ.

Toxins (Basel) · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.3390/toxins10100380

Bibliografisk träff 2016-08-25

Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.

Lewin M, Samuel S, Merkel J, Bickler P.

Toxins (Basel) · research-article; journal article · DOI 10.3390/toxins8090248

Bibliografisk träff 2011-12-01

Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.

Rosenson RS, Fraser H, Goulder MA, Hislop C.

Cardiovasc Drugs Ther · randomized controlled trial; journal article · DOI 10.1007/s10557-011-6344-2

Bibliografisk träff 2011-01-01

After FRANCIS: next steps in the clinical evaluation of varespladib methyl.

Rosenson RS.

Future Cardiol · clinical trial, phase ii; journal article · DOI 10.2217/fca.10.118

Bibliografisk träff 2011-01-01

Varespladib.

Författaruppgift saknas

Am J Cardiovasc Drugs · review; journal article · DOI 10.2165/11533650-000000000-00000

Bibliografisk träff 2010-10-01

Varespladib methyl in cardiovascular disease.

Rosenson RS, Fraser H, Trias J, Hislop C.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2010.517193

Bibliografisk träff 2010-09-01

Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.

Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D.

J Am Coll Cardiol · clinical trial, phase ii; randomized controlled trial; journal article · DOI 10.1016/j.jacc.2010.06.015

Bibliografisk träff 2009-09-01

Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.

Karakas M, Koenig W.

IDrugs · journal article

Bibliografisk träff 2005-03-01

A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.

Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD.

J Rheumatol · clinical trial; research support, non-u.s. gov't; randomized controlled trial; journal article

Go to research.

Publications in the selection

The design and discovery of phospholipase A<sub>2</sub> inhibitors for the treatment of inflammatory diseases.

Varespladib (LY315920) inhibits neuromuscular blockade induced by Oxyuranus scutellatus venom in a nerve-muscle preparation.

Varespladib Inhibits the Phospholipase A<sub>2</sub> and Coagulopathic Activities of Venom Components from Hemotoxic Snakes.

Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms.

Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?

The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites.

Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of <i>Micrurus fulvius</i> (Eastern Coral Snake) Venom.

Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom.

Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.

Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.

After FRANCIS: next steps in the clinical evaluation of varespladib methyl.

Varespladib.

Varespladib methyl in cardiovascular disease.

Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.

Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.

A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.